Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/42032
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSILVA, Paula P. B.-
dc.contributor.authorPEREIRA, Rosa M. R.-
dc.contributor.authorTAKAYAMA, Liliam-
dc.contributor.authorBORBA, Clarissa G.-
dc.contributor.authorDUARTE, Felipe H.-
dc.contributor.authorTRARBACH, Ericka B.-
dc.contributor.authorMARTIN, Regina Matsunaga-
dc.contributor.authorBRONSTEIN, Marcello D.-
dc.contributor.authorTRITOS, Nicholas A.-
dc.contributor.authorJALLAD, Raquel S.-
dc.date.accessioned2021-10-20T13:55:45Z-
dc.date.available2021-10-20T13:55:45Z-
dc.date.issued2021-
dc.identifier.citationJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.106, n.9, p.2690-2706, 2021-
dc.identifier.issn0021-972X-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/42032-
dc.description.abstractContext: Acromegaly can impair bone integrity, increasing the risk of vertebral fractures (VFs). Objective: To evaluate the impact of isolated GH/IGF-I hypersecretion on bone turnover markers, Wnt inhibitors, bone mineral density (BMD), microarchitecture, bone strength and vertebral fractures in female patients with acromegaly (Acro), compared with healthy control group (HC). Design, setting, and patients: Cross-sectional study including 83 premenopausal women without any pituitary deficiency:18 acromegaly in remission (AcroR), 12 in group with active acromegaly (AcroA), and 53 HC. Serum procollagen type 1 N-terminal propeptide, beta-carboxy-terminal crosslinked telopeptide of type 1 collagen, osteocalcin, sclerostin, and DKK1 were measured in blood samples. dual-energy X-ray absorptiometry, high-resolution peripheral quantitative computed tomography (HR-pQCT) and vertebral fractures evaluation were also assessed simultaneously. Main outcome and results: AcroA showed significantly lower sclerostin and higher DKK1 compared with HC. On HR-pQCT of tibia and radius, Acro showed impairment of trabecular (area and trabecular number), increased cortical porosity, and increased cortical area and cortical thickness compared with HC. The only significant correlation found with HR-pQCT parameters was a positive correlation between cortical porosity and serum DKK1 (R= 0.45, P= 0.044). Mild VFs were present in approximately 30% of patients. Conclusions: Eugonadal women with acromegaly without any pituitary deficiency showed increased cortical BMD, impairment of trabecular bone microstructure, and increased VF. Sclerostin was not correlated with any HR-pQCT parameters; however, DKK1 was correlated with cortical porosity in tibia (P= 0.027). Additional studies are needed to clarify the role of Wnt inhibitors on bone microarchitecture impairment in acromegaly.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/23765-0]-
dc.description.sponsorshipConselho Nacional de Ciencia e Tecnologia (CNPQ)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [30556/2017-7]-
dc.language.isoeng-
dc.publisherENDOCRINE SOCeng
dc.relation.ispartofJournal of Clinical Endocrinology & Metabolism-
dc.rightsrestrictedAccesseng
dc.subjectacromegalyeng
dc.subjectgrowth hormoneeng
dc.subjectbone microarchitectureeng
dc.subjectvertebral fractureseng
dc.subjectbone mineral densityeng
dc.subjectWnt signaling pathwayeng
dc.subject.otherquantitative computed-tomographyeng
dc.subject.othervertebral fracture assessmenteng
dc.subject.otherquality-of-lifeeng
dc.subject.othergrowth-factor-ieng
dc.subject.othermineral densityeng
dc.subject.otherimpact microindentationeng
dc.subject.otherdisease-activityeng
dc.subject.othertrabecular boneeng
dc.subject.othercortical boneeng
dc.subject.othersclerostineng
dc.titleImpaired Bone Microarchitecture in Premenopausal Women With Acromegaly: The Possible Role of Wnt Signalingeng
dc.typearticleeng
dc.rights.holderCopyright ENDOCRINE SOCeng
dc.identifier.doi10.1210/clinem/dgab260-
dc.identifier.pmid33871626-
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalTRITOS, Nicholas A.:Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA 02114 USA-
hcfmusp.description.beginpage2690-
hcfmusp.description.endpage2706-
hcfmusp.description.issue9-
hcfmusp.description.volume106-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000692625700016-
hcfmusp.origem.id2-s2.0-85114381655-
hcfmusp.publisher.cityWASHINGTONeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAlswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970weng
hcfmusp.relation.referenceAlvarenga JC, 2017, OSTEOPOROSIS INT, V28, P1335, DOI 10.1007/s00198-016-3876-0eng
hcfmusp.relation.referenceAlvarenga JC, 2018, BONE, V117, P47, DOI 10.1016/j.bone.2018.09.009eng
hcfmusp.relation.referenceBelaya Z, 2018, EUR J ENDOCRINOL, V178, P353, DOI 10.1530/EJE-17-0772eng
hcfmusp.relation.referenceBolanowski M, 2006, J BONE MINER METAB, V24, P72, DOI 10.1007/s00774-005-0649-9eng
hcfmusp.relation.referenceBonadonna S, 2005, J BONE MINER RES, V20, P1837, DOI 10.1359/JBMR.050603eng
hcfmusp.relation.referenceCANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908eng
hcfmusp.relation.referenceChiloiro S, 2018, PITUITARY, V21, P302, DOI 10.1007/s11102-018-0873-7eng
hcfmusp.relation.referenceClynes MA, 2020, OSTEOPOROSIS INT, V31, P1779, DOI 10.1007/s00198-020-05435-8eng
hcfmusp.relation.referenceCosta AG, 2017, BONE, V96, P24, DOI 10.1016/j.bone.2016.10.012eng
hcfmusp.relation.referenceOliveira BD, 2019, PITUITARY, V22, P601, DOI 10.1007/s11102-019-00991-7eng
hcfmusp.relation.referenceDe Mare A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093199eng
hcfmusp.relation.referenceDelgado-Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152eng
hcfmusp.relation.referenceDelgado-Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011eng
hcfmusp.relation.referenceDelgado-Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007eng
hcfmusp.relation.referenceEller-Vainicher C, 2019, EUR J ENDOCRINOLeng
hcfmusp.relation.referenceEZZAT S, 1993, J CLIN ENDOCR METAB, V76, P1452, DOI 10.1210/jc.76.6.1452eng
hcfmusp.relation.referenceFormenti AM, 2019, REV ENDOCR METAB DIS, V20, P295, DOI 10.1007/s11154-019-09507-xeng
hcfmusp.relation.referenceFuller H, 2015, REV BRAS REUMATOL, V55, P352, DOI [10.1016/j.rbr.2014.07.010, 10.1016/j.rbre.2014.07.010]eng
hcfmusp.relation.referenceGenant HK, 2000, J CLIN DENSITOM, V3, P281, DOI 10.1385/JCD:3:3:281eng
hcfmusp.relation.referenceGENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915eng
hcfmusp.relation.referenceGenant HK, 1996, J BONE MINER RES, V11, P984eng
hcfmusp.relation.referenceGiustina A, 2020, TRENDS ENDOCRIN MET, V31, P274, DOI 10.1016/j.tem.2020.01.011eng
hcfmusp.relation.referenceGuo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007eng
hcfmusp.relation.referenceHO PJ, 1992, J NUCL MED, V33, P1608eng
hcfmusp.relation.referenceHUBSCH P, 1993, RADIOLOGE, V33, P457eng
hcfmusp.relation.referenceKaji H, 2001, CLIN ENDOCRINOL, V55, P175, DOI 10.1046/j.1365-2265.2001.01280.xeng
hcfmusp.relation.referenceKayath MJ, 1997, OSTEOPOROSIS INT, V7, P226, DOI 10.1007/BF01622293eng
hcfmusp.relation.referenceKhosla S, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa111eng
hcfmusp.relation.referenceKirkwood BR, 2006, ESSENTIAL MED STAT, V2ndeng
hcfmusp.relation.referenceKOTZMANN H, 1993, J BONE MINER RES, V8, P459eng
hcfmusp.relation.referenceKuo TH, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1452-5eng
hcfmusp.relation.referenceLattanzio S, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001000eng
hcfmusp.relation.referenceLewis JR, 2019, J BONE MINER RES, V34, P2052, DOI 10.1002/jbmr.3830eng
hcfmusp.relation.referenceLi XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200eng
hcfmusp.relation.referenceLopes JB, 2011, OSTEOPOROSIS INT, V22, P711, DOI 10.1007/s00198-010-1258-6eng
hcfmusp.relation.referenceLopes JB, 2012, CLINICS, V67, P1401, DOI 10.6061/clinics/2012(12)09eng
hcfmusp.relation.referenceMadeira M, 2013, J CLIN DENSITOM, V16, P238, DOI 10.1016/j.jocd.2012.06.002eng
hcfmusp.relation.referenceMadeira M, 2013, J CLIN ENDOCR METAB, V98, P1734, DOI 10.1210/jc.2012-4073eng
hcfmusp.relation.referenceMaffezzoni F, 2016, ENDOCRINE, V54, P532, DOI 10.1007/s12020-016-1078-3eng
hcfmusp.relation.referenceMagkos F, 2006, OSTEOPOROSIS INT, V17, P304, DOI 10.1007/s00198-004-1679-1eng
hcfmusp.relation.referenceMakitie RE, 2020, J BONE MINER RES, V35, P901, DOI 10.1002/jbmr.3959eng
hcfmusp.relation.referenceMalgo F, 2017, EUR J ENDOCRINOL, V176, P339, DOI 10.1530/EJE-16-0808eng
hcfmusp.relation.referenceMalgo F, 2017, J BONE MINER RES, V32, P2375, DOI 10.1002/jbmr.3239eng
hcfmusp.relation.referenceMason JJ, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/460120eng
hcfmusp.relation.referenceMazziotti G, 2013, J CLIN ENDOCR METAB, V98, P3402, DOI 10.1210/jc.2013-1460eng
hcfmusp.relation.referenceMazziotti G, 2008, J CLIN ENDOCR METAB, V93, P4649, DOI 10.1210/jc.2008-0791eng
hcfmusp.relation.referenceMazziotti G, 2019, EUR J ENDOCRINOL, V181, pR45, DOI 10.1530/EJE-19-0184eng
hcfmusp.relation.referenceMazziotti G, 2015, J CLIN ENDOCR METAB, V100, P384, DOI 10.1210/jc.2014-2937eng
hcfmusp.relation.referenceMelmed S, 2020, NEW ENGL J MED, V382, P937, DOI 10.1056/NEJMra1810772eng
hcfmusp.relation.referenceMelmed S, 2018, NAT REV ENDOCRINOL, V14, P552, DOI 10.1038/s41574-018-0058-5eng
hcfmusp.relation.referenceMOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075eng
hcfmusp.relation.referenceOftadeh R, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4029176eng
hcfmusp.relation.referenceOtt SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005-2370eng
hcfmusp.relation.referencePadova G, 2011, CLIN CASES MINER BON, V8, P37eng
hcfmusp.relation.referencePaggiosi MA, 2014, CALCIFIED TISSUE INT, V94, P191, DOI 10.1007/s00223-013-9798-3eng
hcfmusp.relation.referencePapaioannou A, 2003, OSTEOPOROSIS INT, V14, P677, DOI 10.1007/s00198-003-1423-2eng
hcfmusp.relation.referencePekkolay Z, 2020, J CLIN ENDOCR METAB, V105, P920, DOI 10.1210/clinem/dgz254eng
hcfmusp.relation.referencePelsma ICM, 2020, EUR J ENDOCRINOL, V183, P427, DOI 10.1530/EJE-20-0415eng
hcfmusp.relation.referencePistoia W, 2002, BONE, V30, P842, DOI 10.1016/S8756-3282(02)00736-6eng
hcfmusp.relation.referencePlayford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297eng
hcfmusp.relation.referencePontes J, 2020, J ENDOCRINOL INVEST, V43, P163, DOI 10.1007/s40618-019-01096-5eng
hcfmusp.relation.referencePontremoli M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35119-7eng
hcfmusp.relation.referenceQiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood-2008-01-132134eng
hcfmusp.relation.referenceQiu SJ, 2006, J BONE MINER RES, V21, P1791, DOI 10.1359/JBMR.060801eng
hcfmusp.relation.referenceRAY WD, 1991, J OPER RES SOC, V42, P815, DOI 10.2307/2583665eng
hcfmusp.relation.referenceSaad CGS, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4055eng
hcfmusp.relation.referenceSantos AM, 2018, CLIN RHEUMATOL, V37, P795, DOI 10.1007/s10067-017-3957-2eng
hcfmusp.relation.referenceSchousboe JT, 2013, J CLIN DENSITOM, V16, P455, DOI 10.1016/j.jocd.2013.08.004eng
hcfmusp.relation.referenceScillitani A, 1997, J BONE MINER RES, V12, P1729, DOI 10.1359/jbmr.1997.12.10.1729eng
hcfmusp.relation.referenceSEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570eng
hcfmusp.relation.referenceShi JF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9295313eng
hcfmusp.relation.referenceShuhart CR, 2019, J CLIN DENSITOM, V22, P453, DOI 10.1016/j.jocd.2019.07.001eng
hcfmusp.relation.referenceSilva PPB, 2017, EUR J ENDOCRINOL, V177, P409, DOI 10.1530/EJE-17-0468eng
hcfmusp.relation.referenceSingh A, 2019, DRUG DISCOV THER, V13, P22, DOI 10.5582/ddt.2019.01011eng
hcfmusp.relation.referenceSzulc P, 2011, J BONE MINER RES, V26, P1358, DOI 10.1002/jbmr.319eng
hcfmusp.relation.referenceTamada D, 2014, ENDOCR J, V61, P231, DOI 10.1507/endocrj.EJ13-0387eng
hcfmusp.relation.referenceUeland T, 2006, EUR J ENDOCRINOL, V155, P709, DOI 10.1530/eje.1.02285eng
hcfmusp.relation.referenceUeland T, 2019, ARTERIOSCL THROM VAS, V39, P294, DOI 10.1161/ATVBAHA.118.311042eng
hcfmusp.relation.referenceUeland T, 2015, J CLIN ENDOCR METAB, V100, P736, DOI 10.1210/jc.2014-2912eng
hcfmusp.relation.referenceValassi E, 2019, ENDOCR CONNECT, V8, P39, DOI 10.1530/EC-18-0482eng
hcfmusp.relation.referenceValassi E, 2016, ENDOCRINE, V53, P860, DOI 10.1007/s12020-016-0945-2eng
hcfmusp.relation.referenceValassi E, 2016, EUR J ENDOCRINOL, V174, P107, DOI 10.1530/EJE-15-0931eng
hcfmusp.relation.referencevan Lierop AH, 2014, J CLIN ENDOCR METAB, V99, pE252, DOI 10.1210/jc.2013-3278eng
hcfmusp.relation.referencevan Lierop AH, 2017, BONE, V96, P51, DOI 10.1016/j.bone.2016.10.010eng
hcfmusp.relation.referenceVokes T, 2016, J CLIN DENSITOM, V19, P5, DOI 10.1016/j.jocd.2014.11.004eng
hcfmusp.relation.referenceWassenaar MJE, 2011, EUR J ENDOCRINOL, V164, P475, DOI 10.1530/EJE-10-1005eng
hcfmusp.relation.referenceWassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P4671, DOI 10.1210/jc.2009-1172eng
hcfmusp.relation.referenceWeivoda MM, 2017, BONE, V96, P45, DOI 10.1016/j.bone.2016.11.024eng
hcfmusp.relation.referenceWhittier DE, 2020, OSTEOPOROSIS INT, V31, P1607, DOI 10.1007/s00198-020-05438-5eng
hcfmusp.relation.referenceWhittier DE, 2020, OSTEOPOROSIS INT, V31, P567, DOI 10.1007/s00198-019-05214-0eng
hcfmusp.relation.referenceWitcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673eng
hcfmusp.relation.referenceXu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00057eng
hcfmusp.relation.referenceYamauchi Mika, 2016, Clin Calcium, V26, P65, DOI CliCa16016572eng
hcfmusp.relation.referenceYang F, 2010, BIOCHEM BIOPH RES CO, V400, P684, DOI 10.1016/j.bbrc.2010.08.128eng
hcfmusp.relation.referenceYang JJ, 2019, CALCIFIED TISSUE INT, V105, P37, DOI 10.1007/s00223-019-00542-zeng
hcfmusp.relation.referenceZhang S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239547eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1945-7197-
hcfmusp.citation.scopus12-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/IPq
Instituto de Psiquiatria - HC/IPq

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/25
LIM/25 - Laboratório de Endocrinologia Celular e Molecular

Artigos e Materiais de Revistas Científicas - LIM/42
LIM/42 - Laboratório de Hormônios e Genética Molecular


Files in This Item:
File Description SizeFormat 
art_SILVA_Impaired_Bone_Microarchitecture_in_Premenopausal_Women_With_Acromegaly_2021.PDF
  Restricted Access
publishedVersion (English)3.1 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.